Cigna (CI) CAO receives 657 options and new stock awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cigna Group Chief Accounting Officer Jamie G. Kates reported equity compensation changes. On February 27, 2026, Kates was granted 657 employee stock options and additional shares of common stock as part of strategic performance share settlements and new restricted share awards. The options and restricted shares vest in three equal annual installments beginning March 1, 2027. A total of 71 and 61 shares of common stock were withheld to satisfy tax obligations tied to these awards, leaving Kates with 2,368 common shares directly owned.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Kates Jamie G

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	657	$0.00	--
Grant/Award	Common Stock, $.01 Par Value	205	$0.00	--
Grant/Award	Common Stock, $.01 Par Value	609	$0.00	--
Tax Withholding	Common Stock, $.01 Par Value	71	$287.55	$20K
Tax Withholding	Common Stock, $.01 Par Value	61	$287.55	$18K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 657 shares (Direct); Common Stock, $.01 Par Value — 1,891 shares (Direct)

Footnotes (1)

The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. These restricted shares vest in three equal annual installments beginning March 1, 2027. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. This option vests in three equal annual installments beginning March 1, 2027.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 07:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kates Jamie G

(Last)

(First)

(Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD

06002

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $.01 Par Value	02/27/2026		A		205⁽¹⁾	A	$0	1,891	D
Common Stock, $.01 Par Value	02/27/2026		A		609⁽²⁾	A	$0	2,500	D
Common Stock, $.01 Par Value	02/27/2026		F		71⁽³⁾	D	$287.55	2,429	D
Common Stock, $.01 Par Value	02/27/2026		F		61⁽⁴⁾	D	$287.55	2,368	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$287.5475	02/27/2026		A		657		03/01/2027⁽⁵⁾	02/27/2036	Common Stock, $.01 Par Value	657	$0	657	D

Explanation of Responses:

1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.

2. These restricted shares vest in three equal annual installments beginning March 1, 2027.

3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.

4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

5. This option vests in three equal annual installments beginning March 1, 2027.

Remarks:

	Tyler Gratton, attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Cigna (CI) insider Jamie G. Kates report in this Form 4?

Jamie G. Kates reported new equity compensation and related tax withholdings. The filing shows grants of stock options and common shares, plus shares withheld to cover tax obligations tied to performance and restricted stock awards over the 2023–2025 period.

How many Cigna (CI) stock options were granted to Jamie G. Kates?

Kates received a grant of 657 employee stock options with a reported exercise price of $0.00 per share. These options vest in three equal annual installments beginning March 1, 2027, aligning with Cigna’s long-term incentive structure for senior executives and linking compensation to multi-year performance.

What common stock awards did Jamie G. Kates receive from Cigna (CI)?

Kates received common shares through settlement of strategic performance shares and a new restricted share grant. The performance shares related to the 2023–2025 period, with payouts based on Company performance goals. The restricted shares vest in three equal annual installments starting March 1, 2027.

Why were some Cigna (CI) shares disposed of in Jamie G. Kates’ Form 4?

The filing shows dispositions of 71 and 61 common shares as tax-withholding transactions, not market sales. These shares were withheld to satisfy tax obligations upon settlement of strategic performance shares and vesting of restricted shares, a common administrative feature of equity compensation programs.

How many Cigna (CI) shares does Jamie G. Kates own after these transactions?

After the reported grants and tax withholdings, Kates directly owns 2,368 shares of Cigna common stock. This figure reflects the net result of equity awards received and shares withheld for taxes on February 27, 2026, as disclosed in the Form 4 filing.

How are Cigna (CI) performance shares linked to executive compensation in this filing?

The reported common stock includes shares received from settlement of strategic performance shares for the 2023–2025 period. The number of shares delivered was based on actual performance against pre-established Company performance goals, directly tying part of Kates’ compensation to Cigna’s multi-year results.